Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023.
Romain DemeulemeesterNicolas SavyMichaël MouniéLaurent MolinierCyrille DelpierrePierre DellamonicaClotilde AllavenaPascal PugliesseLise CuzinPhilippe Saint-PierreNadège CostaPublished in: BMC health services research (2022)
This economic savings simulation could help decision makers to anticipate resource allocations for further innovation in antiretrovirals therapies as well as prevention, especially by funding the Pre-Exposure Prophylaxis (PrEP) or HIV screening.